EUVIMEDEUVIMED entdecken
KorrekturOpen Access · CC BY 4.0

Correction to “Targeting T Cell–Mediated Inflammation: Clinical Benefits of Lifitegrast in Improving Symptoms and Signs of Dry Eye Disease”

Journal of Ophthalmology · 2026-01 · 2026 (1)

DOI: 10.1155/joph/9857150 ↗

Kurz gefasst

Korrektur in der Zeitschrift Journal of Ophthalmology, online erschienen am 05.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

[This corrects the article DOI: 10.1155/joph/9973882.].

Zitieren

APA

(2026). Correction to “Targeting T Cell–Mediated Inflammation: Clinical Benefits of Lifitegrast in Improving Symptoms and Signs of Dry Eye Disease”. Journal of Ophthalmology, 2026(1). https://doi.org/10.1155/joph/9857150

Vancouver

Correction to “Targeting T Cell–Mediated Inflammation: Clinical Benefits of Lifitegrast in Improving Symptoms and Signs of Dry Eye Disease”. Journal of Ophthalmology. 2026;2026(1). doi:10.1155/joph/9857150

BibTeX
@article{euvimed2026,
  title = {Correction to “Targeting T Cell–Mediated Inflammation: Clinical Benefits of Lifitegrast in Improving Symptoms and Signs of Dry Eye Disease”},
  journal = {Journal of Ophthalmology},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/joph/9857150}
}
Kostenlos starten →